Company intelligence / Profile preview

Incro Pharmaceuticals

United States

Ownership: Private
Employees: ~9
Development stage: Other

Overview

Incro developed small molecule, CNS-penetrant RIPK1 inhibitors for neurodegenerative and inflammatory diseases. Lead asset data is limited—after Denali’s acquisition, DNL747 (originating from Incro) reached phase 1 but later development was halted due to toxicity and lack of efficacy.

Therapeutic areas: ImmunologyNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Had license/collaboration with Harvard University for RIPK1 technology (prior to Denali acquisition)

Beyond the preview

Go deeper on Incro Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Incro Pharmaceuticals.

Explore the full profile